Clinical, immunopathogenic, and therapeutic aspects of psoriatic arthritis

Current Opinion in Rheumatology

Volumn 9, Issue 4, 1997, Pages 295-301

  FitzGerald, Oliver ^a   Kane, David ^a  

^a ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN; CYCLOSPORIN; HLA ANTIGEN; HLA ANTIGEN CLASS 1; METHOTREXATE; SALAZOSULFAPYRIDINE;

ARTHRITIS; BLOOD TOXICITY; CLINICAL FEATURE; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG CHOICE; ENTERITIS; GASTROINTESTINAL SYMPTOM; GENETICS; HUMAN; IMMUNOPATHOGENESIS; JOINT DESTRUCTION; LIVER TOXICITY; NEPHROTOXICITY; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; PSORIATIC ARTHRITIS; QUESTIONNAIRE; REVIEW; SPONDYLOARTHROPATHY; SYNOVIUM; T LYMPHOCYTE;

ARTHRITIS, PSORIATIC; HUMANS;

EID: 0030809037     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002281-199707000-00004     Document Type: Review

References (60)

1. Gladman DD, Farewell VT, Nadeau C: Clinical indicators of progression in psoriatic arthritis: multivariate relative risk model. J Rheumatol 1995, 22:675-679.
2. Blackmore MG, Gladman DD, Husted J, Long JA, Farewell VT: Measuring health status in psoriatic arthritis: the Health Assessment Questionnaire and its modification. J Rheumatol 1995, 22:886-893. Although it is currently being used in studies of PsA, this study demonstrates the limitations of the Health Assessment Questionnaire.
3. Husted JA, Gladman DD, Long JA, Farewell VT: A modified version of the Health Assessment Questionnaire (HAQ) for psoriatic arthritis. Clin Exp Rheumatol 1995, 13:439-443.
4. Wright V: Psoriatic arthritis. Ann Rheum Dis 1961, 20:123-132.
5. Helliwell PJ, Wright V: Seronegative spondarthritides. Ballieres Clin Rheumatol 1987, 1:491-523.
6. Ruzicka T: Psoriatic arthritis: new types, new treatments [editorial]. Arch Dermatol 1996, 132:215-219. A concise and topical review of the extra-articular osseus manifestations of PsA and of novel therapeutic agents.
7. Goupille P, Vedere V, Roulot B, Brunais J, Valat JP: Incidence of osteoperiostitis of the great toe in psoriatic arthritis. J Rheumatol 1996, 23:1553-1556.
8. Boisseau-Garsaud AM, Beylot-Barry M, Doutre MS, Beylot C, Baran R: Psoriatic onycho-pachydermo-periostitis: a variant of psoriatic distal interphalangeal arthritis? Arch Dermatol 1996, 132:176-180.
9. Mejjad O, Daragon A, Louvel JP, Da Silva LF, Thomine E, Lauret P, Le Loet X: Osteoarticular manifestations of pustulosis palmaris et plantaris and of psoriasis: two distinct entities. Ann Rheum Dis 1996, 55:177-180.
10. Toussirot E, Dupond JL, Wendling D: Spondylodiscitis in SAPHO syndrome: a series of eight cases. Ann Rheum Dis 1997, 56:52-58.
11. Alonso JC, Lopez-Longo FJ, Lampreave JL, Gonzalez CM, Vegazo O, Carreno L, Almoguera I: Abdominal scintigraphy using 99mTc-HMPAO-labelled leucocytes in patients with seronegative spondylarthropathies without clinical evidence of inflammatory bowel disease. Eur J Nucl Med 1996, 23:243-246.
12. Alonso JC, Lopez-Longo FJ, Lampreave JL, Gonzalez CM, Gonzalez M, Almoguera I, Carreno L: Different abdominal scintigraphy pattern in patients with ulcerative colitis, Crohn's disease and seronegative spondylarthropathies. Br J Rheumatol 1995, 34:946-950.
13. Schatteman L, Mielants H, Veys EM, Cuvelier C, De Vos M, Gyselbrecht L, Elewaut D, Goemaere S: Gut inflammation in psoriatic arthritis: a prospective ileocolonoscopic study. J Rheumatol 1995, 22:680-683. Subclinical intestinal inflammation is present in in psoriatic spondyloarthropathy but not in psoriatic polyarthritis.
14. Winchester R: Psoriatic arthritis. Dermatol Clin 1995, 13:779-792. An excellent and up-to-date review of PsA.
15. Gladman DD, Farewell VT: The role of HLA antigens as indicators of disease progression in psoriatic arthritis. Arthritis Rheum 1995, 6:845-850. HLA class I antigens B27 and B39 and class II antigen DQW 3 are risk factors for disease progression in PsA.
16. Tomfohrde J, Silverman A, Barnes R, Fernandez-Vina MA, Young M, Lory D, Morris L, Wuepper KD, Stastny P, Menter A, Bowcock A: Gene for familial psoriasis susceptibility mapped to distal end of human chromosome 17q. Science 1994, 265:1141-1145.
17. Nair RP, Guo SW, Jenisch S, Henseler T, Lange EM, Terhune M, Westphal E, Christophers E, Voorhees JJ, Elder JT: Scanning chromosome 17 for psoriasis susceptibility: lack of evidence for a distal 17q locus. Hum Heredity 1995, 45:219-230.
18. Matthews D, Fry L, Dowles A, Weissenbach J, Williamson R: Confirmation of genetic heterogeneity in familial psoriasis. J Med Genet 1995, 32:546-548.
19. Veale D, Yanni G, Rogers S, Barnes L, Bresnihan B, FitzGerald O: Reduced synovial membrane macrophage numbers, ELAM-1 expression, and lining layer hyperplasia psoriatic arthritis. Arthritis Rheum 1993, 36:893-900.
20. Punzi L, Bertazzolo N, Pianon M, Michelotto M, Cesaro G, Gambari PF: The volume of synovial fluid effusion in psoriatic arthritis [letter]. Clin Exp Rheumatol 1995, 13:535-536.
21. Howell WM, Warren CJ, Cook NJ, Cawley MI, Smith JL: Detection of IL-2 at mRNA and protein levels in synovial infiltrates from inflammatory arthropathies using biotinylated oligonucleotide probes in situ. Clin Exp Immunol 1991, 86:393-398.
22. Wong WM, Howell WM, Coy SD, Cawley MID, Smith JL: Interleukin-2 is found in the synovium of psoriatic arthritis and spondyloarthritis, not in rheumatoid arthritis. Scan J Rheumatol 1996, 25:239-245. The synovial expression of IL-2 appears to distinguish between RA and PsA/spondyloarthropathy (present), suggesting different pathogenetic mechanisms.
23. Summers KL, O'Donnell JL, Williams LA, Hart DNJ: Expression and function of CD80 and CD86 co-stimulator molecules on synovial dendritic cells in chronic arthritis. Arthritis Rheum 1996, 8:1287-1291. Dendritic cells may be defective antigen-presenting cells in RA but express low levels of costimulatory molecules, CD80 and CD86, in PsA. These differences, which may be significant, need further exploration.
24. Picker LJ, Michie SA, Rott LS, Butcher EC: A unique phenotype of skin associated lymphocytes in humans: preferential expression of the HECA-452 epitope by benign and malignant T cells at cutaneous sites. Am J Pathol 1990, 135:1053-1068.
25. Pitzalis C, Cauli A, Pipitone N, Smith C, Barker J, Marchesoni A, Yann G, Panayi GS: Cutaneous lymphocyte antigen-positive T lymphocytes preferentially migrate to the skin but not the joint in psoriatic arthritis. Arthritis Rheum 1996, 39:137-145. Cutaneous lymphocyte antigen-positive T cells preferentially accumulate in the skin but not in the joints of patients with PsA.
26. Waase I, Kayser C, Carlson PJ, Goronzy JJ, Weyand CM: Oligoclonal T cell proliferation in patients with rheumatoid arthritis and their unaffected siblings. Arthritis Rheum 1996, 39:904-913. Clonally expanded CD4+ T cells are present in RA and their unaffected siblings but not in patients with PsA.
27. Geczy AF, Sullivan JS: Possible role of HLA-B27 associated cytotoxic T lymphocyte activity in the pathogenesis of the seronegative arthropathies. Ann Rheum Dis 1995, 54:329-330.
28. Sieper J, Braun J: Pathogenesis of spondyloarthropathies: persistent bacterial antigen, autoimmunity, or both? Arthritis Rheum 1995, 38:1547-1554.
29. Hermann E, Yu DTY, Meyer zum Buschenfelde K-H, Fleischer B: HLA-B27-restricted CD8 T cells derived from synovial fluids of patients with reactive arthritis and ankylosing spondylitis. Lancet 1993, 342:646-650.
30. Scofield RH, Kurien B, Gross T, Warren WL, Harley JB: HLA-B27 binding of peptide from its own sequence and similar peptides from bacteria: implications for spondyloarthropathies. Lancer 1995, 345:1542-1544.
31. Taurog JD, Richardson JA, Croft JT, Simmons WA, Zhou M, Fernandez-Sueiro JL, Balish E, Hammer RE: The germfree state prevents development of gut and joint inflammatory disease in HLA-B27 transgenic rats. J Exp Med 1994, 180:2359-2364.
32. Rath HC, Herfarth HH, Ikeda JS, Grenther WB, Hamm TE Jr, Balish E, Taurog JD, Hammer RE, Wilson KH, Sartor RB: Normal luminal bacteria, especially Bacteroides species, mediate chronic colitis, gastritis and arthritis in HLA-B27/Human β2 microglobulin transgenic rats. J Clin Invest 1996, 98:945-953.
33. Valdimarsson H, Baker BS, Jonsdottir I, Powles A, Fry L: Psoriasis: a T cell-mediated autoimmune disease induced by streptococcal super-antigens? Immunol Today 1995, 16:145-149.
34. Schon MP, Detmar M, Parker EM: Murine psoriasis-like disorder induced by naive CD4+ T cells: Nature Med 1997, 3:183-188. Reconstruction of SCID/SCID mice with minor histocompatibility mismatched naive CD4+ T lymphocytes resulted in skin alterations that bore a striking resemblance to human psoriasis.
35. Paukkonen R: The development of manifest psoriatic lesions is linked with the invasion of CD8+ T cells and CD11c + macrophages into the epidermis: Arch Dermatol Res 1992, 284:375-379.
36. Gottlieb SL, Gilleaudeau P, Johnson R, Estes L, Woodworth TG, Gottlieb AB, Krueger JG: Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nature Med 1995, 1:442-447. Fascinating paper suggesting that psoriasis is mediated by lymphocytes and not keratinocytes.
37. Chang JCC, Smith LR, Froning KJ, Schwabe BJ, Laxer JA, Caralli LL, Kurland HH, Karasek MA, Wilkinson DI, Carlo DJ, Brostoff SW: CD8+ T cells in psoriatic lesions preferentially use T cell receptos Vβ3 and/or Vβ13.1 genes. Proc Natl Acad Sci U S A 1994, 91:9282-9286. This study demonstrated preferential use of Vβ3 and Vβ13.1 in epidermally-derived CD8 T cells but not in the CD4+ T-cell population.
38. Wrone-Smith T, Johnston T, Nelson B, Boise LH, Thompson CB, Nunez G, Nickoloff BJ: Discordant expression of Bc1-x and Bc1-2 by keratinocytes in vitro and psoriatic keratinocytes in vivo. Am J Pathol 1995, 146:1079-1088.
39. Creamer JD, Barker JNWN: Vascular proliferation and angiogenic factors in psoriasis. Clin Exp Dermatol 1995, 20:6-9.
40. Lowe PM, Lee ML, Jackson CJ, To S-ST, Cooper AJ, Schrieber L: The endothelium in psoriasis. Br J Dermatol 1995, 132:497-505.
41. Goupille P, Valat JP: Sulfasalazine in psoriatic arthritis: a new or established indication [letter]? Arthritis Rheum 1996, 39:711-712.
42. Gupta AK, Grober JS, Hamilton TA, Ellis CN, Siegel MT, Voorhees JJ, McCune WJ: Sulfasalazine therapy for psoriatic arthritis: a double blind, placebo controlled trial. J Rheumatol 1995, 22:894-898.
43. Dougados M, vam der Linden S, Leirisalo-Repo M, Huitfeldt B, Juhlin R, Veys E, Zeidler H, Kvien TK, Olivieri I, Dijkmans B, Bertouch J, Brooks P, Edmonds J, Major G, Amor B, Calin A: Sulfasalazine in the treatment of spondylarthropathy: a randomized, multicenter, double-blind, placebo-controlled study. Arthritis Rheum 1995, 38:618-627. An excellent study of Sulfasalazine, 3 g/d, in spondyloarthropathy confirms its anti-inflammatory efficacy and safety, particularly in the PsA subgroup.
44. Combe B, Goupille, Kuntz JL, Tebib J, Liotes F, Bregeon C: Sulphasalazine in psoriatic arthritis: a randomised multicentre, placebo-controlled study. Br J Rheumatol 1996, 35:664-668.
45. Spadaro A, Riccieri V, Sili-Scavalli A, Sensi F, Taccari E, Zoppini A: Comparison of cyclosporin A and methotrexate in the treatment of psoriatic arthritis: a one-year prospective study. Clin Exp Rheumatol 1995, 13:589-593. Cyclosporine and methotrexate have similar anti-inflammatory efficacy but different side-effect profiles.
46. Abu-Shakra M, Gladman DD, Thorne JC, Long J, Gough J, Farewell VT: Longterm methotrexate therapy in psoriatic arthritis: clinical and radiological outcome. J Rheumatol 1995, 22:241-245. A case-control study in a small number of patients (n = 19) on methotrexate therapy for PsA demonstrates clinical response but no effect on radiologic progression.
47. Gomez-Vaquero C, Rodriguez-Moreno J, Ros S, Marcos R, Fiter J, Roig-Escofet D: Termination of disease-modifying drugs in psoriatic arthritis: study of 109 courses of treatment. Br J Rheumatol 1996, 35:564-567.
48. Erickson AR, Reddy V, Vogelgesang SA, West SG: Usefulness of the American College of Rheumatology recommendations for liver biopsy in methotrexate-treated rheumatoid arthritis patients. Arthritis Rheum 1995, 38:1115-1119.
49. Hassan W: Methotrexate and liver toxicity: role of surveillance liver biopsy. Conflict between guidelines for rheumatologists and dermatologists. Ann Rheum Dis 1996, 55:273-275. This excellent review emphasizes the disparity in recommendations for the safety monitoring of methotrexate in RA, psoriasis, and PsA.
50. Boffa MJ, Smith A, Chalmers RJG, Mitchell DM, Rowan B, Warnes TW, Shomaf M, Haboubi NY: Serum type III procollagen aminopeptide for assessing liver damage in methotrexate-treated psoriatic patients. Br J Dermatol 1996, 135:538-544.
51. Zonneveld IM, Bakker WK, Dijkstra PF, Bos JD, van Soesbergen RM, Dinant HJ: Methotrexate osteopathy in long-term, low-dose methotrexate treatment for psoriasis and rheumatoid arthritis. Arch Dermatol 1996, 132:184-187.
52. Masson C, Chennebault JM, Leclech C: Is HIV infection contraindication to the use of methotrexate in psoriatic arthritis [letter]? J Rheumatol 1995, 22:2191.
53. Grossman RM, Chevret S, Abi-Rached J, Blanchet F, Dubertret L: Long-term safety of cyclosporine in the treatment of psoriasis. Arch Dermatol 1996, 132:623-629. This study reports a high incidence of side effects but identifies risk markers for cyclosporine toxicity.
54. Bourke JF, Berth-Jones J, Holder J, Graham-Brown RA: A new microemulsion formulation of cyclosporin (Neoral) is effective in the treatment of cyclosporin-resistant dermatoses. Br J Dermatol 1996, 134:777-779.
55. Elder CA, Moore M, Chang CT, Jin J, Charnick S, Nedelman J, Cohen A, Guzzo C, Lowe N, Simpson K: Efficacy and pharmokinetics of two formulations of cyclosporine A in patients with psoriasis. J Clin Pharmacol 1995, 35:865-875.
56. Michel G, Kemeny L, Homey B, Ruzicka T: FK506 in the treatment of inflammatory skin disease: promises and perspectives. Immunol Today 1996, 17:106-110. This excellent review of the use of tacrolimus in inflammatory skin disease gives reference to its possible mechanisms of action.
57. Rappersburger K, Meingasser JG, Fialla R, Fodinger D, Sterniczy B, Rauch S, Putz E, Stutz A, Wolff K: Clearing of psoriasis by a novel immunosuppressive macrolide. J Invest Dermatol 1996, 106:701-710.
58. Eibschutz B, Baird SM, Weisman MH, Amox DG, Spellman M, Piacquadio D, Carrera CJ, Carson DA: Oral 2-chlorodeoxyadenosine in psoriatic arthritis: a preliminary report. Arthritis Rheum 1995, 38:1604-1609.
59. Eulry F, Mayaudon H, Bauduceau B, Lechevalier D, Crozes P, Magnin J, Claude-Berthelot C: Blood prolactin under the effect of protirelin in spondylarthropathies: treatment trial of 4 cases of reactive arthritis and 2 cases of psoriatic arthritis with bromocriptine. Ann Med Interne (Paris) 1996, 147:15-19.
60. Eulry F, Mayaudon H, Lechevalier D, Bauduceau B, Ariche L, Ouakil H, Crozes P, Magnin J: Treatment of rheumatoid psoriasis with bromocriptine. Presse Med 1995, 24:1642-1644.